descriptionPublicationkeyboard_double_arrow_right Article 01 Nov 2001 English Publisher:Ovid Technologies (Wolters Kluwer Health)Journal:Dimensions of Critical Care Nursing, volume 20, pages 19-23 (issn: 0730-4625,

Authors: Sabadie-Garretson W; De Jong Mj;

doi: 10.1097/00003465-200111000-00006

pmid: 22076580

Tenecteplase: A promising new fibrinolytic agent

- Summary
- Subjects
- Metrics

Abstract

Acute coronary syndrome can mean anything from unstable angina to acute myocardial infarction (MI) with ST-segment elevation. Tenecteplase, a new fibrinolytic agent used to treat ST-segment elevation acute MI, has some advantages over other fibrinolytic agents. This article describes tenecteplase's actions, indications, contraindications, and use.

Related Organizations

AUS (United States)
United States
East Jefferson General Hospital
United States

Keywords

Male, Fibrinolytic Agents, Tissue Plasminogen Activator, Tenecteplase, Humans, Acute Coronary Syndrome, Drug Monitoring, Middle Aged

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average